The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Ivan Butula - One of the best experts on this subject based on the ideXlab platform.
-
macromolecular prodrugs v polymer Broxuridine conjugates
International Journal of Pharmaceutics, 1995Co-Authors: Branka Zorc, Dusica Maysinger, Igor Kalcic, Ivan ButulaAbstract:Abstract Broxuridine (BrdU) was covalently bound to α,β-poly[(2-hydroxyethyl)- dl -aspartamide](PHEA) and α,β-poly[(2-aminoethyl)-DL-aspartamide]-α,β-poly[(2-hydroxyethyl)-DL-aspartamide](PAHA). BrdU was first chemically modified to 3′- O -acetyl-5′- O -chloroformyl-5-bromo-2′-deoxyuridine (AcCBrdU) and 3′- O -acetyl-5′- O -phosphooxydichloride-5-bromo-2′-deoxyuridine (AcPBrdU). These compounds were bound to PHEA by carbonate and phosphodiester linkages, respectively. 5-Bromo-2′-deoxyuridine 5′-monophosphate (PBrdU) was linked to PAHA by an amide type bond. Neuroepithelial cells were used as a model system to assess the suitability of the conjugated BrdU for cell proliferation. Parallel experiments were performed with unconjugated BrdU and the extent of incorporation into DNA was determined by immunocytochemistry using an BrdU antibody. The results from these studies suggest that conjugated BrdU can be used as an alternative to currently used means of BrdU delivery.
Branka Zorc - One of the best experts on this subject based on the ideXlab platform.
-
macromolecular prodrugs v polymer Broxuridine conjugates
International Journal of Pharmaceutics, 1995Co-Authors: Branka Zorc, Dusica Maysinger, Igor Kalcic, Ivan ButulaAbstract:Abstract Broxuridine (BrdU) was covalently bound to α,β-poly[(2-hydroxyethyl)- dl -aspartamide](PHEA) and α,β-poly[(2-aminoethyl)-DL-aspartamide]-α,β-poly[(2-hydroxyethyl)-DL-aspartamide](PAHA). BrdU was first chemically modified to 3′- O -acetyl-5′- O -chloroformyl-5-bromo-2′-deoxyuridine (AcCBrdU) and 3′- O -acetyl-5′- O -phosphooxydichloride-5-bromo-2′-deoxyuridine (AcPBrdU). These compounds were bound to PHEA by carbonate and phosphodiester linkages, respectively. 5-Bromo-2′-deoxyuridine 5′-monophosphate (PBrdU) was linked to PAHA by an amide type bond. Neuroepithelial cells were used as a model system to assess the suitability of the conjugated BrdU for cell proliferation. Parallel experiments were performed with unconjugated BrdU and the extent of incorporation into DNA was determined by immunocytochemistry using an BrdU antibody. The results from these studies suggest that conjugated BrdU can be used as an alternative to currently used means of BrdU delivery.
Dusica Maysinger - One of the best experts on this subject based on the ideXlab platform.
-
macromolecular prodrugs v polymer Broxuridine conjugates
International Journal of Pharmaceutics, 1995Co-Authors: Branka Zorc, Dusica Maysinger, Igor Kalcic, Ivan ButulaAbstract:Abstract Broxuridine (BrdU) was covalently bound to α,β-poly[(2-hydroxyethyl)- dl -aspartamide](PHEA) and α,β-poly[(2-aminoethyl)-DL-aspartamide]-α,β-poly[(2-hydroxyethyl)-DL-aspartamide](PAHA). BrdU was first chemically modified to 3′- O -acetyl-5′- O -chloroformyl-5-bromo-2′-deoxyuridine (AcCBrdU) and 3′- O -acetyl-5′- O -phosphooxydichloride-5-bromo-2′-deoxyuridine (AcPBrdU). These compounds were bound to PHEA by carbonate and phosphodiester linkages, respectively. 5-Bromo-2′-deoxyuridine 5′-monophosphate (PBrdU) was linked to PAHA by an amide type bond. Neuroepithelial cells were used as a model system to assess the suitability of the conjugated BrdU for cell proliferation. Parallel experiments were performed with unconjugated BrdU and the extent of incorporation into DNA was determined by immunocytochemistry using an BrdU antibody. The results from these studies suggest that conjugated BrdU can be used as an alternative to currently used means of BrdU delivery.
Igor Kalcic - One of the best experts on this subject based on the ideXlab platform.
-
macromolecular prodrugs v polymer Broxuridine conjugates
International Journal of Pharmaceutics, 1995Co-Authors: Branka Zorc, Dusica Maysinger, Igor Kalcic, Ivan ButulaAbstract:Abstract Broxuridine (BrdU) was covalently bound to α,β-poly[(2-hydroxyethyl)- dl -aspartamide](PHEA) and α,β-poly[(2-aminoethyl)-DL-aspartamide]-α,β-poly[(2-hydroxyethyl)-DL-aspartamide](PAHA). BrdU was first chemically modified to 3′- O -acetyl-5′- O -chloroformyl-5-bromo-2′-deoxyuridine (AcCBrdU) and 3′- O -acetyl-5′- O -phosphooxydichloride-5-bromo-2′-deoxyuridine (AcPBrdU). These compounds were bound to PHEA by carbonate and phosphodiester linkages, respectively. 5-Bromo-2′-deoxyuridine 5′-monophosphate (PBrdU) was linked to PAHA by an amide type bond. Neuroepithelial cells were used as a model system to assess the suitability of the conjugated BrdU for cell proliferation. Parallel experiments were performed with unconjugated BrdU and the extent of incorporation into DNA was determined by immunocytochemistry using an BrdU antibody. The results from these studies suggest that conjugated BrdU can be used as an alternative to currently used means of BrdU delivery.
Hiroomi Takahashi - One of the best experts on this subject based on the ideXlab platform.
-
A combined therapy for maxillary cancer
Gan to kagaku ryoho. Cancer & chemotherapy, 1991Co-Authors: Hiroomi TakahashiAbstract:: Forty-three patients with cancer of the maxillary sinus were treated by surgery combined with radiation and regional chemotherapy as a series of treatment in 1978-1989. The combined therapy consisted of the followings: 1) Operation to reduce tumor-mass. 2) Irradiation of total dose of 16 Gy, that is, 8 Gy preoperatively and 8 Gy postoperatively. 3) Chemotherapy with arterial infusion of 1,000 mg fluorouracil (5-FU) and 2,000 mg Broxuridine (BUdR) for 4 days after operation. Of the 16 patients with neck metastasis, 14 accepted extirpation of the metastatic cervical lymph nodes and upper neck dissection was performed in other 2 cases. Five-year survival was 87% in the 32 patients of stage II and III but 41% in the 11 of stage IV. The combined therapy for patients of stage II and III disease is recommended because of the satisfactory results. However, a further study is required in our therapeutic schema for the case of stage IV since the prognosis was poor.
